PET/CT Imaging of Chemokine Receptors in Inflammatory Atherosclerosis Using Targeted Nanoparticles
暂无分享,去创建一个
Craig J. Hawker | Pamela K. Woodard | Robert J. Gropler | Eric D. Pressly | Yongjian Liu | R. Gropler | C. Hawker | P. Woodard | Yongjian Liu | L. Detering | H. Luehmann | G. Randolph | Gwendalyn J. Randolph | B. Fors | Brett P. Fors | Lisa Detering | Hannah P. Luehmann
[1] D. Greaves,et al. Chemokines, Chemokine Receptors and Atherosclerosis , 2005 .
[2] Michael J Welch,et al. Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. , 2012, Bioconjugate chemistry.
[3] A. Zernecke,et al. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. , 2006, Blood.
[4] F. Mach,et al. Differential Expression Patterns of Proinflammatory and Antiinflammatory Mediators During Atherogenesis in Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[5] G. Randolph,et al. Local apoptosis mediates clearance of macrophages from resolving inflammation in mice. , 2013, Blood.
[6] J. Jukema,et al. Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? , 2007, Current pharmaceutical design.
[7] W. Kuziel,et al. CC chemokine receptor 5 influences late-stage atherosclerosis. , 2007, Atherosclerosis.
[8] Craig J Hawker,et al. Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer. , 2013, Bioconjugate chemistry.
[9] Christian Weber,et al. Chemokines in Atherosclerosis , Thrombosis , and Vascular Biology Series Editor : Christian Weber Chemokines in Atherosclerosis An Update , 2008 .
[10] Oliver Soehnlein,et al. Chemokines control mobilization, recruitment, and fate of monocytes in atherosclerosis. , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[11] R. Ross,et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[12] Joel A. Cohen,et al. Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. , 2009, Molecular pharmaceutics.
[13] D. Wagner,et al. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. , 2000, Circulation.
[14] F. Mach,et al. The specific role of chemokines in atherosclerosis , 2007, Thrombosis and Haemostasis.
[15] D. Greaves,et al. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics , 2004, Current opinion in lipidology.
[16] Eric D. Pressly,et al. Targeting Angiogenesis Using a C-Type Atrial Natriuretic Factor–Conjugated Nanoprobe and PET , 2011, The Journal of Nuclear Medicine.
[17] Sébastien Perrier,et al. Macromolecular design via réversible addition-fragmentation chain transfer (RAFT)/Xanthates (MADIX) polymerization , 2005 .
[18] Yiran Wang,et al. C‐Terminal Incorporation of Bio‐Orthogonal Azide Groups into a Protein and Preparation of Protein–Oligodeoxynucleotide Conjugates by CuI‐Catalyzed Cycloaddition , 2007, Chembiochem : a European journal of chemical biology.
[19] M. Jerath,et al. Chemokine Receptors in Atherosclerosis , 2007 .
[20] R. Pierce,et al. PET Imaging of Chemokine Receptors in Vascular Injury–Accelerated Atherosclerosis , 2013, The Journal of Nuclear Medicine.
[21] R. Horuk,et al. Chemokine receptor antagonists: overcoming developmental hurdles , 2009, Nature Reviews Drug Discovery.
[22] A. Zernecke,et al. Chemokines in the vascular inflammatory response of atherosclerosis. , 2010, Cardiovascular research.
[23] F. Tacke,et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.
[24] R. Horuk,et al. Promiscuous drugs as therapeutics for chemokine receptors , 2009, Expert Reviews in Molecular Medicine.
[25] Eric D. Pressly,et al. PET/CT Imaging of Chemokine Receptor CCR5 in Vascular Injury Model Using Targeted Nanoparticle , 2014, The Journal of Nuclear Medicine.
[26] D. Greaves,et al. CC Chemokine Receptors and Chronic Inflammation—Therapeutic Opportunities and Pharmacological Challenges , 2013, Pharmacological Reviews.
[27] A. Zernecke,et al. Molecular Imaging of Inflammation in Atherosclerosis , 2013, Theranostics.
[28] D. Ly,et al. Nanoparticle for delivery of antisense γPNA oligomers targeting CCR5 , 2013, Artificial DNA, PNA & XNA.
[29] J. Rudd,et al. PET imaging of inflammation in atherosclerosis , 2014, Nature Reviews Cardiology.
[30] F. Mach,et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. , 2006, Atherosclerosis.
[31] R. Westrick,et al. Murine models of vascular thrombosis (Eitzman series). , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[32] R. Ransohoff,et al. The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.
[33] D. Rader,et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. , 2011, The Journal of clinical investigation.
[34] Ralph Weissleder,et al. Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis , 2008, Circulation.
[35] P. Libby. Inflammation in atherosclerosis , 2002, Nature.
[36] K. Moore,et al. Macrophages in atherosclerosis: a dynamic balance , 2013, Nature Reviews Immunology.
[37] Daniel G. Anderson,et al. Therapeutic siRNA silencing in inflammatory monocytes , 2011, Nature Biotechnology.